Cyclophosphamide + Etoposide + Methotrexate

This is a chemotherapy combination regimen that has been studied and used in various cancer treatments, particularly for gestational trophoblastic tumors and certain types of lymphomas. The combination appears in several clinical studies, sometimes with additional agents such as actinomycin D and vincristine, forming regimens like EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide, and Vincristine)[1][2][3]. ### Mechanism of Action Each component of this combination has a distinct mechanism: - **Cyclophosphamide**: An alkylating agent that cross-links DNA strands, preventing cell division and leading to cell death. It's particularly effective against rapidly dividing cells. - **Etoposide**: A topoisomerase II inhibitor that prevents DNA unwinding and replication, causing DNA strand breaks and cell death. - **Methotrexate**: An antimetabolite that inhibits dihydrofolate reductase, preventing the formation of tetrahydrofolate which is necessary for DNA synthesis and cell division. ### Clinical Applications The combination has been studied in: 1. **Gestational Trophoblastic Disease**: Studies show high effectiveness for metastatic, high-risk gestational trophoblastic tumors with 100% survival rates in some studies[1]. 2. **CNS Metastases of Choriocarcinoma**: When used in the EMA/CO regimen, it showed 72% disease-free survival in patients who presented with CNS metastases[2][3]. 3. **Lymphomas**: Various combinations including these drugs have been studied in non-Hodgkin lymphoma treatments[5][6]. ### Toxicity Profile Common side effects reported include: - Neutropenia (requiring treatment delays in some cases) - Anemia (occasionally requiring transfusion) - Peripheral neuropathy (primarily from vincristine when included) - Nausea and vomiting - Diarrhea - Stomatitis - Alopecia - Conjunctivitis - Thrombocytopenia - Fever[1] Despite these side effects, studies indicate the combination is generally well-tolerated, with manageable toxicity profiles when appropriate supportive care is provided. ### Administration The administration schedule varies by protocol, but often involves: - Weekly alternating schedules (in EMA/CO regimens) - Specific dosing adjustments based on patient factors - Methotrexate doses ranging from standard to high-dose (up to 1 g/m²) depending on the specific protocol and disease being treated[2][3] This combination represents an important treatment option for specific high-risk cancers, particularly gestational trophoblastic diseases, where it has demonstrated significant efficacy.